Dan Zhang, M.D., Ph.D.

Dr. Zhang is the executive chair of Fountain Medical Development Ltd, a clinical research organization with 1,700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia and the U.S. He previously served as head of clinical development and head of safety assessment at Sigma-Tau Research Inc., a leading Italian pharmaceutical company; as vice president at Quintiles Transnational Corp.; and as chair of Quintiles Medical Development (Shanghai) Company Ltd. 

He is a member of the grant review committee for the National Drug Development Fund of China and is a consultant for the China Food and Drug Administration (CFDA). He is a member of the ICH E19 Expert Working Group; chair of the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association; and is a senior consultant for the Chinese Academy of Medical Sciences and Peking Union Medical College. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China; was on the board of directors for the Sino-American Pharmaceutical Association and was the former president of the Chinese Biopharmaceutical Association-USA. 

He is chairing the government relationship committee of Bayhelix, an organization hosting senior executives from life-science organizations in the U.S. and China. He was a senior consultant to Peking Union Medical College and the Chinese Academy of Medical Sciences.

Dr. Zhang received an M.D. from Peking Union Medical College, an M.P.H. from the Harvard School of Public Health, and an M.B.A. in healthcare management from the Wharton Business School of the University of Pennsylvania.